Guidance rise was widely anticipated .. vaccines sales missed which caused the drop. Fwiw I added a bit to my holding at 15 quid |
Update very positive, markets up but GSK down. 🤷 |
Added a few more at just under 1502p |
Does anyone understand the fall? What is the rationale? Or is it better to simply accept that markets are irrational? |
Just hold - long term this is a bargain! |
I'll be adding my third and final tranche today for a long term hold in my ISA |
GSK can't catch a break! Raises guidance and still falls |
Lols ridiculous opening |
GSK, a pharmaceutical group, reported that 2Q core rose 13% on year at constant exchange rates to 43.4 pence. The company lifted its full-year core EPS growth guidance to 10% - 12% from 8% - 10% previously. |
Aye can't grumble at that .. just need the Zantac issue to clear up. |
 Healthy numbers..
GSK delivers continued strong performance and upgrades 2024 guidance
Broad-based performance drives sales, core profit and core EPS growth:
•
Total Q2 2024 sales £7.9 billion +13%
•
Vaccines sales +1%, +3% ex COVID. Shingrix £0.8 billion -4%
•
Specialty Medicines sales +22%. HIV sales +13%. Oncology sales more than doubled at £0.4 billion
•
General Medicines sales +12%. Trelegy £0.8 billion +41%
•
Total operating profit -22% and Total EPS -27% for Q2 2024 primarily reflected higher charges for CCL(1) remeasurements driven by improved longer term HIV prospects and foreign currency movements
•
Core operating profit +18% (with further positive impact of 3% ex COVID) and Core EPS +13% (with further positive impact of 4% ex COVID). This reflected continued leverage from strong sales and favourable product and regional mix, partly offset by continued increased investment in R&D and growth assets, and lower royalty income
•
Cash generated from operations in the quarter £1.7 billion with Free cash flow of £0.3 billion
(Financial Performance - Q2 2024 results unless otherwise stated, growth % and commentary at CER, ex COVID is excluding COVID-19 solutions |
Does this mean we going down to £15 tomorrow |
LONDON and CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
This alliance brings together GSK's disease area expertise and development capability with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies, to make major advances in healthcare.
GSK and Flagship will initially fund up to $150 million upfront to support an exploration phase to identify the most promising concepts for further research and development with Flagship's bioplatform companies. From these explorations, the collaboration aims to identify a portfolio of up to 10 novel medicines and vaccines which will each be subject to an exclusive option by GSK for further clinical development. |
TraderMichael
Post 33172
"In April, Public Health England reported the results of a large study of COVID-19 transmission involving more than 365,000 households with a mix of vaccinated and unvaccinated members"
Interesting. Wasnt aware of this particular study.
So presumably you'll be getting your next covid jab then?
How many times have you had covid btw. I've had it at least twice as far as I am aware.
Zero Covid 19 vaccinations here. And I wont take the FLU vaccine either because they are going to make it a bivalent one(so you get Flu + Covid19 latest strain)
FYI I know of my several family members who have suffered "severe adverse events" post their 3rd Jab and will not take any more.
And as to excess deaths globally in countries with high vaccination rates.
Wonder that is all about.
Wil lwe ever get told the truth?
Decent news from GSK this morning has to be said. |
dplwise1 - that these claimants are settling like this indicates to me that the closer they get to a trial the weaker they feel their case is. Its likely that others will be deterred (and their ambulance-chasing lawyers) who are seeking mega-payouts rather than genuinely wanting to have their 'day in court' and are now prepared to take some money (and run).
There is no causal evidence that scientifically proves a direct link between Zantac itself and these unfortunate peoples' cancers. |
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of GSK’s respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract disease (LRTD) caused by RSV from adults aged 60 and above to include adults aged 50-59 years at increased risk for RSV disease.
Today’s positive opinion is the first time that an indication for adults aged 50-59 has been recommended by CHMP for a RSV vaccine, one of the final steps prior to the extension of the marketing authorisation by the European Commission. The European Commission’s final decision is expected by September 2024. Since June 2023, Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) has been approved in Europe for adults aged 60 and over for the prevention of RSV-LRTD. |
Zantac settlement with Ronald Kimbrow .. case now dismissed. Not a fan of this tbh I'm sure there are benefits to GSK but to the layman it just seems like as admission of guilt |
Nice to see a bounce off the 12 month TA support trend line at 1500, almost predictable.. :o), where to next..? the Zantac cases have not gone away, but oversold now down from the 1800 May high.. |
In April, Public Health England reported the results of a large study of COVID-19 transmission involving more than 365,000 households with a mix of vaccinated and unvaccinated members.
It found immunisation with either the Pfizer or AstraZeneca vaccine reduced the chance of onward virus transmission by 40-60%. This means that if someone became infected after being vaccinated, they were only around half as likely to pass their infection on to others compared to infected people who weren’t vaccinated. |
TraderMichael
There was never any evidence that the Covid vaccines prevented transmission but they were foisted on everyone who couldnt afford to say NO regardless.
Chance these jabs delay Dementia minimal.
All part of the sales gimmick to encourage uptake.
And NO I wont be taking my Flu vaccine annually either. |
Interesting that the study was not performed by GSK. Its hard to see the pathway on how it would work, but the data set is already substantial. I doubt it will ever be recommended as a prevention but it may increase the uptake of shingrix. There is a little more here |
But there's evidence:
Researchers compared some 100,000 people who had a new (GSK) shingles jab to a similar group who had an older one. On average, those who had the new jab had an extra 164 days free from a diagnosis of dementia over six years. Further work is needed to prove the link, scientists say. |
>>Stock price chart suggests the yanks are the ones trading on the short side here
Yes, that's quite likely, especially considering the problems are mostly caused by US ambulance chasers. |
Shingles could delay Dementia.
Yeah righto.
You're the last person I'd expect to fall for that speculative gusto |
Would be a big market... |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
